Journal Information
Signal Transduction and Targeted Therapy (ISSN 2059-3635 (online), ISSN 2095-9907 (print), CN 51-1758/R) is an open access journal, which aims to accomplish timely publication of the latest discoveries and progress in both basic science and clinical research related to signal transduction and targeted therapy. It will include research on major human diseases, such as cancer, autoimmune disorders and others.
Signal Transduction and Targeted Therapy is a multidisciplinary journal, covering topics including but not limited to molecular biology, cell biology, pharmacology, medicinal chemistry, computational chemistry, systems biology, bioinformatics, and clinical medicine.
The editorial team of Signal Transduction and Targeted Therapy is composed of a highly respected editorial board of researchers from across the globe, led by the internationally renowned Professor Carlo M. Croce, together with Professor Kang Zhang and Professor Yu-Quan Wei.
This journal is now indexed in Science Citation Index Expanded (SCIE), Journal Citation Reports/Science Edition, BIOSIS previews, Directory of Open Access Journals (DOAJ), MEDLINE, PubMed Central (PMC) and Scopus.
Why publish in Signal Transduction and Targeted Therapy?
- Publishes latest discoveries & progress related to signal transduction & targeted therapy.
- Affiliated with West China Hospital, Sichuan University.
- High visibility for your work with open access.
Journal Metrics
Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.
Citation Impact 2023
- Journal Impact Factor: 40.8
- 5-year Journal Impact Factor: 40.5
- Source Normalized Impact per Paper (SNIP): 5.308
- SCImago Journal Rank (SJR): 8.737
Speed 2023
- Submission to first editorial decision (median days): 8
- Submission to acceptance (median days): 140
Usage 2023
- Downloads: 6,303,379
- Altmetric mentions: 17,019
Disclaimer
The editorial policies of this publication are determined jointly by its Editorial Board and Springer Nature in accordance with the legal and regulatory requirements of China.